CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research methodology
1.4.1. Primary research
1.4.2. Secondary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO Perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top impacting factors
3.2.2. Top investment pockets
3.3. Porter’s five forces analysis
3.3.1. Low bargaining power of suppliers
3.3.2. Low threat of new entrants
3.3.3. Low threat of substitutes
3.3.4. Low intensity of rivalry
3.3.5. Low bargaining power of buyers
3.4. Market dynamics
3.4.1. Drivers
3.4.1.1. Increase in geriatric population and rise in awareness regarding fibrin sealants
3.4.1.2. Growth in the prevalence of chronic diseases and rise in the number of surgical procedures conducted globally
3.4.2. Restraints
3.4.2.1. High cost of fibrin sealants and availability of alternate products
3.4.3. Opportunities
3.4.3.1. Growth opportunities in emerging countries
CHAPTER 4: FIBRIN SEALANTS MARKET, BY DOSAGE FORMS
4.1. Overview
4.1.1. Market size and forecast
4.2. Liquid
4.2.1. Key market trends, growth factors and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market share analysis by country
4.2.4. Liquid Fibrin Sealants Market by Liquid Type
4.3. Patch
4.3.1. Key market trends, growth factors and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market share analysis by country
4.4. Powder
4.4.1. Key market trends, growth factors and opportunities
4.4.2. Market size and forecast, by region
4.4.3. Market share analysis by country
CHAPTER 5: FIBRIN SEALANTS MARKET, BY APPLICATION
5.1. Overview
5.1.1. Market size and forecast
5.2. General Surgery
5.2.1. Key market trends, growth factors and opportunities
5.2.2. Market size and forecast, by region
5.2.3. Market share analysis by country
5.3. Cardiovascular Surgery
5.3.1. Key market trends, growth factors and opportunities
5.3.2. Market size and forecast, by region
5.3.3. Market share analysis by country
5.4. Wound Management
5.4.1. Key market trends, growth factors and opportunities
5.4.2. Market size and forecast, by region
5.4.3. Market share analysis by country
5.5. Orthopedic Surgery
5.5.1. Key market trends, growth factors and opportunities
5.5.2. Market size and forecast, by region
5.5.3. Market share analysis by country
5.6. Urological Surgeries
5.6.1. Key market trends, growth factors and opportunities
5.6.2. Market size and forecast, by region
5.6.3. Market share analysis by country
5.7. Ophthalmic Surgeries
5.7.1. Key market trends, growth factors and opportunities
5.7.2. Market size and forecast, by region
5.7.3. Market share analysis by country
5.8. Others
5.8.1. Key market trends, growth factors and opportunities
5.8.2. Market size and forecast, by region
5.8.3. Market share analysis by country
CHAPTER 6: FIBRIN SEALANTS MARKET, BY END USER
6.1. Overview
6.1.1. Market size and forecast
6.2. Hospitals
6.2.1. Key market trends, growth factors and opportunities
6.2.2. Market size and forecast, by region
6.2.3. Market share analysis by country
6.3. Ambulatory Surgical Centers
6.3.1. Key market trends, growth factors and opportunities
6.3.2. Market size and forecast, by region
6.3.3. Market share analysis by country
6.4. Clinics
6.4.1. Key market trends, growth factors and opportunities
6.4.2. Market size and forecast, by region
6.4.3. Market share analysis by country
CHAPTER 7: FIBRIN SEALANTS MARKET, BY REGION
7.1. Overview
7.1.1. Market size and forecast By Region
7.2. North America
7.2.1. Key market trends, growth factors and opportunities
7.2.2. Market size and forecast, by Dosage Forms
7.2.3. Market size and forecast, by Application
7.2.4. Market size and forecast, by End User
7.2.5. Market size and forecast, by country
7.2.5.1. U.S.
7.2.5.1.1. Market size and forecast, by Dosage Forms
7.2.5.1.2. Market size and forecast, by Application
7.2.5.1.3. Market size and forecast, by End User
7.2.5.2. Canada
7.2.5.2.1. Market size and forecast, by Dosage Forms
7.2.5.2.2. Market size and forecast, by Application
7.2.5.2.3. Market size and forecast, by End User
7.2.5.3. Mexico
7.2.5.3.1. Market size and forecast, by Dosage Forms
7.2.5.3.2. Market size and forecast, by Application
7.2.5.3.3. Market size and forecast, by End User
7.3. Europe
7.3.1. Key market trends, growth factors and opportunities
7.3.2. Market size and forecast, by Dosage Forms
7.3.3. Market size and forecast, by Application
7.3.4. Market size and forecast, by End User
7.3.5. Market size and forecast, by country
7.3.5.1. Germany
7.3.5.1.1. Market size and forecast, by Dosage Forms
7.3.5.1.2. Market size and forecast, by Application
7.3.5.1.3. Market size and forecast, by End User
7.3.5.2. France
7.3.5.2.1. Market size and forecast, by Dosage Forms
7.3.5.2.2. Market size and forecast, by Application
7.3.5.2.3. Market size and forecast, by End User
7.3.5.3. UK
7.3.5.3.1. Market size and forecast, by Dosage Forms
7.3.5.3.2. Market size and forecast, by Application
7.3.5.3.3. Market size and forecast, by End User
7.3.5.4. Italy
7.3.5.4.1. Market size and forecast, by Dosage Forms
7.3.5.4.2. Market size and forecast, by Application
7.3.5.4.3. Market size and forecast, by End User
7.3.5.5. Spain
7.3.5.5.1. Market size and forecast, by Dosage Forms
7.3.5.5.2. Market size and forecast, by Application
7.3.5.5.3. Market size and forecast, by End User
7.3.5.6. Rest of Europe
7.3.5.6.1. Market size and forecast, by Dosage Forms
7.3.5.6.2. Market size and forecast, by Application
7.3.5.6.3. Market size and forecast, by End User
7.4. Asia-Pacific
7.4.1. Key market trends, growth factors and opportunities
7.4.2. Market size and forecast, by Dosage Forms
7.4.3. Market size and forecast, by Application
7.4.4. Market size and forecast, by End User
7.4.5. Market size and forecast, by country
7.4.5.1. Japan
7.4.5.1.1. Market size and forecast, by Dosage Forms
7.4.5.1.2. Market size and forecast, by Application
7.4.5.1.3. Market size and forecast, by End User
7.4.5.2. China
7.4.5.2.1. Market size and forecast, by Dosage Forms
7.4.5.2.2. Market size and forecast, by Application
7.4.5.2.3. Market size and forecast, by End User
7.4.5.3. India
7.4.5.3.1. Market size and forecast, by Dosage Forms
7.4.5.3.2. Market size and forecast, by Application
7.4.5.3.3. Market size and forecast, by End User
7.4.5.4. Australia
7.4.5.4.1. Market size and forecast, by Dosage Forms
7.4.5.4.2. Market size and forecast, by Application
7.4.5.4.3. Market size and forecast, by End User
7.4.5.5. South Korea
7.4.5.5.1. Market size and forecast, by Dosage Forms
7.4.5.5.2. Market size and forecast, by Application
7.4.5.5.3. Market size and forecast, by End User
7.4.5.6. Rest of Asia-Pacific
7.4.5.6.1. Market size and forecast, by Dosage Forms
7.4.5.6.2. Market size and forecast, by Application
7.4.5.6.3. Market size and forecast, by End User
7.5. LAMEA
7.5.1. Key market trends, growth factors and opportunities
7.5.2. Market size and forecast, by Dosage Forms
7.5.3. Market size and forecast, by Application
7.5.4. Market size and forecast, by End User
7.5.5. Market size and forecast, by country
7.5.5.1. Brazil
7.5.5.1.1. Market size and forecast, by Dosage Forms
7.5.5.1.2. Market size and forecast, by Application
7.5.5.1.3. Market size and forecast, by End User
7.5.5.2. South Africa
7.5.5.2.1. Market size and forecast, by Dosage Forms
7.5.5.2.2. Market size and forecast, by Application
7.5.5.2.3. Market size and forecast, by End User
7.5.5.3. Saudi Arabia
7.5.5.3.1. Market size and forecast, by Dosage Forms
7.5.5.3.2. Market size and forecast, by Application
7.5.5.3.3. Market size and forecast, by End User
7.5.5.4. Rest of LAMEA
7.5.5.4.1. Market size and forecast, by Dosage Forms
7.5.5.4.2. Market size and forecast, by Application
7.5.5.4.3. Market size and forecast, by End User
CHAPTER 8: COMPETITIVE LANDSCAPE
8.1. Introduction
8.2. Top winning strategies
8.3. Product mapping of top 10 player
8.4. Competitive dashboard
8.5. Competitive heatmap
8.6. Top player positioning, 2022
CHAPTER 9: COMPANY PROFILES
9.1. Baxter International Inc.
9.1.1. Company overview
9.1.2. Key executives
9.1.3. Company snapshot
9.1.4. Operating business segments
9.1.5. Product portfolio
9.1.6. Business performance
9.2. Becton, Dickinson and Company
9.2.1. Company overview
9.2.2. Key executives
9.2.3. Company snapshot
9.2.4. Operating business segments
9.2.5. Product portfolio
9.2.6. Business performance
9.3. Corza Medical
9.3.1. Company overview
9.3.2. Key executives
9.3.3. Company snapshot
9.3.4. Operating business segments
9.3.5. Product portfolio
9.3.6. Key strategic moves and developments
9.4. CSL Behring
9.4.1. Company overview
9.4.2. Key executives
9.4.3. Company snapshot
9.4.4. Operating business segments
9.4.5. Product portfolio
9.4.6. Business performance
9.5. Grifols, S.A.
9.5.1. Company overview
9.5.2. Key executives
9.5.3. Company snapshot
9.5.4. Operating business segments
9.5.5. Product portfolio
9.5.6. Business performance
9.5.7. Key strategic moves and developments
9.6. Hemarus Therapeutics Ltd.
9.6.1. Company overview
9.6.2. Key executives
9.6.3. Company snapshot
9.6.4. Operating business segments
9.6.5. Product portfolio
9.7. Johnson and Johnson
9.7.1. Company overview
9.7.2. Key executives
9.7.3. Company snapshot
9.7.4. Operating business segments
9.7.5. Product portfolio
9.7.6. Business performance
9.8. Nordson Corporation (Nordson Medical)
9.8.1. Company overview
9.8.2. Key executives
9.8.3. Company snapshot
9.8.4. Operating business segments
9.8.5. Product portfolio
9.8.6. Business performance
9.9. Shanghai Raas Blood Products Co. Ltd
9.9.1. Company overview
9.9.2. Key executives
9.9.3. Company snapshot
9.9.4. Operating business segments
9.9.5. Product portfolio
9.10. Vivostat A/S
9.10.1. Company overview
9.10.2. Key executives
9.10.3. Company snapshot
9.10.4. Operating business segments
9.10.5. Product portfolio
| ※参考情報 フィブリンシーラントは、止血や創傷の治癒を助けるために使用される医療用の材料です。フィブリンは血液凝固の過程で形成されるタンパク質であり、フィブリンシーラントはこのフィブリンを主成分とする製品です。主に外科手術や外傷治療において、出血を迅速に止めたり、組織を接着したりする目的で使用されます。 フィブリンシーラントは大きく分けて2種類に分類されます。一つは、単一成分型シーラントで、もう一つは二成分型シーラントです。単一成分型シーラントは、シリンジから直接噴射できる形で提供され、多くの場合、専用の活性化剤を必要とせず、迅速に使用できるのが特徴です。一方、二成分型シーラントは、フィブリノゲンとトロンビンという二つの成分からなり、これらが混合されることでフィブリンが生成され、止血効果を発揮します。 フィブリンシーラントの主な用途は、止血、組織接着、創傷治癒の促進です。外科手術では、特に開腹手術や脳神経外科手術、整形外科手術などで多く使用されます。これにより、出血を抑制し、手術後の回復を早めることが期待されます。また、外傷治療においては、切り傷や抜歯後の止血、皮膚移植の際にも効果を発揮します。最近では、口腔外科や耳鼻咽喉科領域でもその適用が広がっています。 フィブリンシーラントは、生体適合性に優れ、身体に優しい素材であるため、アレルギー反応や異物反応が起こりにくいとされます。しかし、使用の際には患者の個別の状況に応じて適切に選択する必要があります。また、フィブリンシーラントは、必ずしも全ての出血に対して最適ではないため、医師が出血の程度や原因を考慮しながら使うべきです。 関連技術としては、フィブリンシーラント以外に、コラーゲン製品や生体吸収性の糸、剛性接着剤、バイオマテリアルなどもあります。これらは、フィブリンシーラントと併用することで、手術の安全性や効率を高めることができます。特に、組織接着剤や特殊な縫合技術と組み合わせることで、より効果的な創傷治療が可能になります。 最近の研究では、フィブリンシーラントの改良版も開発されています。これには、抗菌性を持たせたり、持続的に薬剤を放出できるタイプのシーラントが含まれます。これによって、感染のリスクを低減し、創傷の治癒過程をさらに迅速にすることが目的です。 また、フィブリンシーラントは血液由来の成分を使用しているため、生物製剤としての特性を持つ一方で、感染症のリスクも考慮しなければなりません。したがって、製造過程では血液の安全性を確保するための厳しい基準が設けられています。このため、フィブリンシーラントは、厳密な品質管理のもとで製造され、使用されることが重要です。 総じて、フィブリンシーラントは創傷治療や止血において広く用いられ、医療の現場で欠かせない存在となっています。その特性や用途を十分に理解し、適切に活用することが求められます。これからも技術の進歩に伴い、さらに多様な用途が期待される分野でもあり、今後の展望に注目が集まっています。 |
*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/
